Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
暂无分享,去创建一个
A. Skene | E. Braunwald | C. Cannon | A. Charlesworth | C. McCabe | E. Braunwald | J. López-Sendón | A. Langer | R. Wilcox | J. Toman | C. McCabe | R. Anders | J. López-Sendón | A. Caspi | J. Alexander | R. G. Wilcox | P. Berink | C. Mccabe | Peter Berink | C. Mccabe
[1] P. Théroux,et al. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. , 2000, Journal of the American College of Cardiology.
[2] P Serruys,et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. , 2000, The New England journal of medicine.
[3] S. Mousa,et al. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[4] C. Cannon,et al. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction. , 2000, The American journal of cardiology.
[5] R. Califf,et al. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial , 2000, The Lancet.
[6] E. Antman,et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.
[7] E. Braunwald,et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. , 1999, Journal of the American College of Cardiology.
[8] David P Miller,et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. , 1998, Circulation.
[9] C. Bode,et al. Induction of Fibrinogen Binding and Platelet Aggregation as a Potential Intrinsic Property of Various Glycoprotein IIb/IIIa (IIbβ3) Inhibitors , 1998 .
[10] E. Topol,et al. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. , 1998, Circulation.
[11] S. Mousa,et al. Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3. , 1998, The Journal of pharmacology and experimental therapeutics.
[12] E. Braunwald,et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. , 1998, Circulation.
[13] Gebhardt,et al. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina , 1998 .
[14] S. Heptinstall,et al. Role of GPIIb-IIIa in platelet-monocyte and platelet-neutrophil conjugate formation in whole blood. , 1998, Platelets.
[15] Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. , 1998, The New England journal of medicine.
[16] B. Coller,et al. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. , 1997, Circulation.
[17] R. Califf,et al. Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention , 1995 .
[18] E. Antman. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. , 1994, Circulation.
[19] Xiaoping Du,et al. Ligands “activate” integrin α IIb β 3 (platelet GPIIb-IIIa) , 1991, Cell.
[20] Xiaoping Du,et al. Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa). , 1991, Cell.
[21] T R Fleming,et al. Designs for group sequential tests. , 1984, Controlled clinical trials.
[22] Cockcroft Dw,et al. Prediction of Creatinine Clearance from Serum Creatinine , 1976 .
[23] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.